155 related articles for article (PubMed ID: 18272913)
1. Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial.
Barrett SV; Paul J; Hay A; Vasey PA; Kaye SB; Glasspool RM;
Ann Oncol; 2008 May; 19(5):898-902. PubMed ID: 18272913
[TBL] [Abstract][Full Text] [Related]
2. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).
Au-Yeung G; Webb PM; DeFazio A; Fereday S; Bressel M; Mileshkin L
Gynecol Oncol; 2014 Apr; 133(1):16-22. PubMed ID: 24680586
[TBL] [Abstract][Full Text] [Related]
3. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
4. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study.
Wright JD; Tian C; Mutch DG; Herzog TJ; Nagao S; Fujiwara K; Powell MA
Gynecol Oncol; 2008 Jun; 109(3):353-8. PubMed ID: 18407341
[TBL] [Abstract][Full Text] [Related]
5. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study.
Hess LM; Barakat R; Tian C; Ozols RF; Alberts DS
Gynecol Oncol; 2007 Nov; 107(2):260-5. PubMed ID: 17675142
[TBL] [Abstract][Full Text] [Related]
6. Impact of obesity on secondary cytoreductive surgery and overall survival in women with recurrent ovarian cancer.
Tran AQ; Cohen JG; Li AJ
Gynecol Oncol; 2015 Aug; 138(2):263-6. PubMed ID: 26037901
[TBL] [Abstract][Full Text] [Related]
7. Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.
Bandera EV; Lee VS; Rodriguez-Rodriguez L; Powell CB; Kushi LH
JAMA Oncol; 2015 Sep; 1(6):737-45. PubMed ID: 26181758
[TBL] [Abstract][Full Text] [Related]
8. Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer.
Vasey PA
J Clin Oncol; 2003 May; 21(10 Suppl):136s-144s. PubMed ID: 12743129
[TBL] [Abstract][Full Text] [Related]
9. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
[TBL] [Abstract][Full Text] [Related]
10. Myelosuppression by chemotherapy in obese patients with gynecological cancers.
Kamimura K; Matsumoto Y; Zhou Q; Moriyama M; Saijo Y
Cancer Chemother Pharmacol; 2016 Sep; 78(3):633-41. PubMed ID: 27485538
[TBL] [Abstract][Full Text] [Related]
11. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
12. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
[TBL] [Abstract][Full Text] [Related]
15. The effect of obesity on survival in patients with ovarian cancer.
Matthews KS; Straughn JM; Kemper MK; Hoskins KE; Wang W; Rocconi RP
Gynecol Oncol; 2009 Feb; 112(2):389-93. PubMed ID: 19062080
[TBL] [Abstract][Full Text] [Related]
16. Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
Becker DA; Thomas ED; Gilbert AL; Boone JD; Straughn JM; Huh WK; Bevis KS; Leath CA; Alvarez RD
Gynecol Oncol; 2016 Jul; 142(1):25-29. PubMed ID: 27130405
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study).
Ueda Y; Miyatake T; Nagamatsu M; Yamasaki M; Nishio Y; Yoshino K; Fujita M; Tsutsui T; Enomoto T; Kimura T
Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):259-63. PubMed ID: 23880598
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer.
Sorbe B; Graflund M; Horvath G; Swahn M; Boman K; Bangshöj R; Lood M; Malmström H
Int J Gynecol Cancer; 2012 Jan; 22(1):47-53. PubMed ID: 22193643
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin-paclitaxel- and carboplatin-docetaxel-induced cytotoxic effect in epithelial ovarian carcinoma in vitro.
Engblom P; Rantanen V; Kulmala J; Grènman S
Cancer; 1999 Nov; 86(10):2066-73. PubMed ID: 10570433
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]